BOSTON and VANCOUVER, BC, November 10, 2025 — Alpha-9 Oncology, Inc., a clinical-stage radiopharmaceutical company pioneering targeted cancer therapies, has announced the appointment of Paul Blanchfield as its new Chief Executive Officer and member of the Board of Directors. Blanchfield, formerly President of Lantheus, brings over 15 years of leadership across radiopharmaceuticals, biotechnology, and healthcare, marking a pivotal moment for Alpha-9 as it advances its pipeline of novel cancer treatments.
Science Significance
Alpha-9 Oncology’s appointment of Paul Blanchfield underscores the company’s scientific ambition to redefine radiopharmaceutical oncology through precision targeting of tumor cells while minimizing damage to healthy tissue. The company’s proprietary molecular design platform has already generated a robust clinical pipeline, featuring highly selective therapeutic candidates with first- and best-in-class potential. Under Blanchfield’s guidance, Alpha-9 aims to accelerate clinical development and expand into validated oncology targets, reinforcing its scientific leadership at the cutting edge of radiation-based cancer therapeutics. His expertise in scaling R&D operations and integrating science-driven strategy positions Alpha-9 to enhance translational outcomes and optimize radiopharma’s next wave of innovation.
Regulatory Significance
As Alpha-9 transitions deeper into early-phase clinical trials, regulatory engagement will be central to ensuring cGxP compliance and clinical integrity. Blanchfield’s background at Lantheus, a commercial-stage radiopharma company operating within a highly regulated environment, adds strategic depth in navigating FDA and EMA frameworks for radiopharmaceutical approvals. His leadership is expected to strengthen Alpha-9’s regulatory readiness, advance Investigational New Drug (IND) submissions, and ensure alignment with Good Manufacturing Practice (GMP) and Good Clinical Practice (GCP) standards. With expanding radiopharmaceutical pipelines attracting increasing scrutiny, this appointment highlights Alpha-9’s commitment to transparency, safety, and regulatory excellence in its global development strategy.
Business Significance
Advertisement
Alpha-9’s appointment comes amid strong corporate momentum, following a $175 million Series C financing led by Lightspeed Venture Partners and Ascenta Capital in late 2024. This financial strength provides a solid foundation for scaling operations, expanding partnerships, and driving commercial readiness for future products. Blanchfield’s record of operational excellence at Lantheus and strategic leadership roles at Takeda and Shire Pharmaceuticals uniquely position him to guide Alpha-9 through its next growth phase. His ability to integrate business acumen with scientific vision is expected to catalyze pipeline advancement, bolster investor confidence, and prepare Alpha-9 for potential strategic alliances or commercialization opportunities in the fast-evolving oncology market.
Patients’ Significance
For patients, Alpha-9’s mission is deeply aligned with improving treatment precision and quality of life for those living with cancer. The company’s highly targeted radiopharmaceuticals are designed to deliver therapeutic radiation directly to tumor cells, sparing surrounding healthy tissue—a vital advancement for reducing side effects and enhancing tolerability. With Blanchfield’s leadership focused on clinical translation and patient access, Alpha-9 is poised to accelerate therapies that could transform cancer care paradigms. The company’s research approach seeks to bridge molecular design with patient-centric outcomes, supporting the broader goal of personalized oncology treatment that delivers both efficacy and safety.
Policy Significance
Alpha-9’s growth under new leadership also signals broader implications for healthcare policy and radiopharma regulation. As global authorities refine guidelines for the development, approval, and reimbursement of radiopharmaceuticals, companies like Alpha-9 are shaping the dialogue around innovation policy, manufacturing standards, and nuclear material handling in clinical settings. Blanchfield’s experience across multinational environments will aid Alpha-9 in engaging constructively with policymakers, ensuring alignment with emerging international standards and advocating for frameworks that facilitate safe and ethical radiopharmaceutical access. This leadership shift reflects the industry’s evolution toward policy-driven innovation, emphasizing accountability and equitable patient benefit.
The appointment of Paul Blanchfield as CEO represents a strategic inflection point for Alpha-9 Oncology as it advances its mission to deliver differentiated, highly targeted radiopharmaceuticals for cancer patients worldwide. Combining scientific innovation with strong regulatory and commercial experience, Alpha-9 is positioning itself as a front-runner in next-generation oncology therapeutics. With a solid financial foundation, an expanding clinical pipeline, and a visionary leader at the helm, Alpha-9 stands ready to transform radiopharma’s potential into tangible, life-changing outcomes for patients.
Source: Alpha-9 Oncology, Inc. press release
